Exon 20 Clinical Trials

10 recruitingLast updated: June 17, 2026

There are 10 actively recruiting exon 20 clinical trials across 26 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Fairfax, Virginia, United States, Paris, France, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Exon 20 Trials at a Glance

10 actively recruiting trials for exon 20 are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Fairfax, Paris, and Barcelona. Lead sponsors running exon 20 studies include Taiho Oncology, Inc., Groupe Francais De Pneumo-Cancerologie, and GFPC Investigation.

Browse exon 20 trials by phase

Treatments under study

About Exon 20 Clinical Trials

Looking for clinical trials for Exon 20? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Exon 20 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Exon 20 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Non-small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament345 enrolled24 locationsNCT06043817
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNSCLC+6 more
GFPC Investigation100 enrolled16 locationsNCT07563205
Recruiting
Not Applicable

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie30 enrolled18 locationsNCT06247826
Recruiting
Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
National Cancer Centre, Singapore600 enrolled3 locationsNCT06418412
Recruiting
Phase 2

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc200 enrolled2 locationsNCT06706713
Recruiting
Phase 2

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD20 enrolled1 locationNCT06192849
Recruiting
Phase 2

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-small Cell Lung CancerMET AmplificationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital30 enrolled1 locationNCT05800340